These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 31466854)
1. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854 [TBL] [Abstract][Full Text] [Related]
2. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693 [TBL] [Abstract][Full Text] [Related]
3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV; N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641 [TBL] [Abstract][Full Text] [Related]
4. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Reck M; Dziadziuszko R; Sugawara S; Kao S; Hochmair M; Huemer F; de Castro G; Havel L; Bernabé Caro R; Losonczy G; Lee JS; Kowalski DM; Andric Z; Califano R; Veatch A; Gerstner G; Batus M; Morris S; Kaul M; Cuchelkar V; Li H; Danner BJ; Nabet BY; Liu SV Lung Cancer; 2024 Oct; 196():107924. PubMed ID: 39306923 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer. Igata F; Inoue H; Ikeda T; Nakao A; Ebi N; Fujita M Anticancer Res; 2024 Jul; 44(7):3175-3183. PubMed ID: 38925816 [TBL] [Abstract][Full Text] [Related]
7. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236 [TBL] [Abstract][Full Text] [Related]
8. IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Nishio M; Saito H; Goto K; Watanabe S; Sueoka-Aragane N; Okuma Y; Kasahara K; Chikamori K; Nakagawa Y; Kawakami T Cancer Sci; 2021 Apr; 112(4):1534-1544. PubMed ID: 33462883 [TBL] [Abstract][Full Text] [Related]
9. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Hida T; Kaji R; Satouchi M; Ikeda N; Horiike A; Nokihara H; Seto T; Kawakami T; Nakagawa S; Kubo T Clin Lung Cancer; 2018 Jul; 19(4):e405-e415. PubMed ID: 29525239 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445 [TBL] [Abstract][Full Text] [Related]
11. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901 [TBL] [Abstract][Full Text] [Related]
12. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L; Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097 [TBL] [Abstract][Full Text] [Related]
13. Atezolizumab: A Review in Extensive-Stage SCLC. Frampton JE Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939 [TBL] [Abstract][Full Text] [Related]
14. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Mansfield AS; Każarnowicz A; Karaseva N; Sánchez A; De Boer R; Andric Z; Reck M; Atagi S; Lee JS; Garassino M; Liu SV; Horn L; Wen X; Quach C; Yu W; Kabbinavar F; Lam S; Morris S; Califano R Ann Oncol; 2020 Feb; 31(2):310-317. PubMed ID: 31959349 [TBL] [Abstract][Full Text] [Related]
15. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957 [TBL] [Abstract][Full Text] [Related]
16. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW; Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988 [TBL] [Abstract][Full Text] [Related]
17. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis. Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610 [TBL] [Abstract][Full Text] [Related]
18. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y; Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956 [TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer. Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698 [TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]